Synaptogenix joins leading neuroscientists and academics as speaker at usc-sponsored forum on age-related diseases including alzheimer's

Presenters, including nobel laureate in medicine, to discuss innovative treatments for neurodegeneration company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe alzheimer's disease (ad) patients new york , dec. 6, 2023 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its president and chief scientific officer, daniel alkon, m.d., will join more than 30 leading neuroscientists and academics as a speaker at iabs forum-2023, "new concepts for the treatment of neurodegenerative disorders.
SNPX Ratings Summary
SNPX Quant Ranking